Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus Target Price from Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $34.50.

Several research firms have recently issued reports on CAPR. HC Wainwright restated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Cantor Fitzgerald increased their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $15.15 on Friday. The firm has a market cap of $688.87 million, a P/E ratio of -14.29 and a beta of 4.08. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The firm’s 50 day moving average price is $14.20 and its 200 day moving average price is $13.20.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. raised its holdings in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the period. The Manufacturers Life Insurance Company raised its stake in Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 2,361 shares during the period. Invesco Ltd. lifted its holdings in Capricor Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 2,500 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 2,947 shares during the last quarter. Finally, Corebridge Financial Inc. boosted its stake in Capricor Therapeutics by 32.2% in the fourth quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 4,434 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.